Opdivo Use For Urothelial Cancer Blocked By NICE In Draft Guidance
Executive Summary
Opdivo has failed to convince the UK's pricing watchdog, NICE, of its value and benefit for patients with advanced urothelial cancer; in its draft decision the reimbursement body has also rejected the drug for use on the Cancer Drugs Fund.
You may also be interested in...
UK’s NICE Backs BMS's Opdivo In Lung Cancer, But Only Via CDF With Price Cut
UK HTA body NICE has decided to make Bristol-Myers Squibb's PD-1 inhibitor Opdivo available for non-small-cell lung cancer, but only through the UK's revamped Cancer Drugs Fund, and at a discounted price.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.